Circulating megakaryocyte and platelet microvesicles correlate with response to ruxolitinib and distinct disease severity in patients with myelofibrosis. (2019)
Attributed to:
Wellcome Trust MRC Cambridge Stem Cell Institute
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1111/bjh.15682
PubMed Identifier: 30450539
Publication URI: http://europepmc.org/abstract/MED/30450539
Type: Journal Article/Review
Volume: 185
Parent Publication: British journal of haematology
Issue: 5
ISSN: 0007-1048